Ventyx biosciences highlights 2025 pipeline strategy and provides clinical updates on its nlrp3 inhibitor portfolio

First subjects dosed in a phase 2 trial of vtx3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in h2 2025
VTYX Ratings Summary
VTYX Quant Ranking